Gelonghui May 15 丨 Jinyao Pharmaceutical (600488.SH) said at the performance briefing that the company has always attached importance to the international market. Up to now, the company's sales of API products have covered more than 70 countries and regions around the world, including South America, Asia and Europe. Some varieties of process technology and product quality have reached the international advanced level, and it is a scientific research, production and export base for steroidal hormone drugs in Asia. In terms of pharmaceutical products, the company has successively commercialized methylprednisolone tablets, prednisone tablets, and injectable methylprednisolone sodium succinate in the US market. Among them, methylprednisolone tablets have maintained a leading share in the US market for 3 consecutive years; in emerging markets, ointments have been exported to East Asia and Africa, injectable methylprednisolone sodium succinate products have been exported to West Asia, and major infusion preparation products from the subsidiary Hubei Jinyao have been exported to Africa. In the future, the company will further broaden its global perspective, implement large-scale and innovative variety strategies, focus on consolidating and developing high-end markets such as Europe and the US, and accelerate the international registration process for new products in emerging markets and speed up the international layout.